نتایج جستجو برای: recombinant human erythropoietin rhuepo

تعداد نتایج: 1714926  

2017
Jeffrey Crawford

The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based o...

Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with sol...

Journal: :Blood 1996
S Elliott D Chang E Delorme C Dunn J Egrie J Giffin T Lorenzini C Talbot L Hesterberg

We have isolated and characterized three anti-recombinant human erythropoietin (rHuEPO) monoclonal antibodies (MoAbs) that recognize nonoverlapping epitopes on rHuEPO. Anti-EPO MoAb D11 neutralizes rHuEPO activity whereas MoAbs F12 and 9G8A do not. This suggests that D11 may bind to the rHuEPO active site. MoAbs F12 and D11 recognize conformation dependent epitopes whereas 9G8A does not. Immuno...

Journal: :Haematologica 2003
Frédéric Baron Pascale Frère Yves Beguin

A, et al. What happens subsequently in AML when cytoge-neetic abnormalities persist at bone marrow harvest? Results of the 10 th UK MRC AML trial. We enrolled 13 recipients of an allogeneic peripheral blood stem cell transplant (PBSCT) in a trial of recombinant human erythropoietin (rHuEpo) therapy (500 U/kg/wk once weekly) started on day 30 after PBSCT. Ten patients who did not receive rHuEpo ...

1994
Robert I. Griffiths Neil R. Powe Joel Greer Gregory de Lissovoy Gerard F. Anderson Paul K. Whelton Alan J. Watson Paul W. Eggers

Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD). In a study of rHuEPO diffusion, costs, and effectiveness, we analyze ESRD program data and all claims submitted to Medicare for reimbursement of rHuEPO administered to ESRD dialysis patients. Access to rHuEPO was rapid and extensive during the first year of Medicare covera...

2017
Hamed M. Osman Osama A. Khamis Mohamed S. Elfeky Amani M. El Amin Ali Mostafa Y. Abdelwahed

INTRODUCTION Insulin resistance (IR) is a known complication of end-stage kidney disease (ESKD). It may be an important therapeutic target in stages of chronic kidney disease. AIM The study was conducted to evaluate the effect of short-term treatment with recombinant human erythropoietin (rHuEpo) therapy on IR, serum leptin, and neuropeptide Y in ESKD patients on hemodialysis. MATERIALS AND...

Journal: :medical journal of islamic republic of iran 0
morteza afrasiabi from the department of obstetrics and gynaecology, royal college of surgeons in ireland, the coombe hospital, dublin zahra zolnoorian from the department of obstetrics and gynaecology, royal college of surgeons in ireland, the coombe hospital, dublin seyyed hossein javadpoor the department of renal medicine, adelide hospital, dublin 8, republic of ireland

the pharmacokinetics of recombinant human erythropoietin (rhuepo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. the half-life of circulating erythropoietin decreased from 7.9±oa hr (mean ±so) at the beginning of treatment to 6.2±o.6 hr after 6 weeks and 5a±o.9 hr after 4 months of treatment. in spite of the s...

Journal: :Journal of analytical toxicology 2005
Françoise Lasne Marie-Agnes Popot Emmanuelle Varlet-Marie Laurent Martin Jean-Antoine Martin Yves Bonnaire Michel Audran Jacques de Ceaurriz

A direct detection method for anti-doping control of recombinant human erythropoietin (rHuEPO) abuse in racehorses is proposed. This method involves screening of plasma (or serum) by an enzyme-linked immunosorbent assay specific for human EPO and confirmation in urine samples by characterization of the urinary EPO isoelectric profile. This method was tested on horses that were administered epoe...

Journal: :European journal of clinical investigation 2005
B Sturm D Stupphann C Kaun S Boesch M Schranzhofer J Wojta H Goldenberg B Scheiber-Mojdehkar

BACKGROUND Friedreich's ataxia (FRDA) is a neurodegenerative disorder caused by decreased expression of the protein frataxin, recently described to be an iron chaperone for the assembly of iron-sulphur clusters in the mitochondria, causing iron accumulation in mitochondria, oxidative stress and cell damage. Searching for compounds that could possibly influence frataxin expression, we found that...

Journal: :Biochemical Society transactions 2005
P J Coussons S Baig C Fanutti R Grant

rHuEPO (recombinant human erythropoietin) is a haemopoietic growth factor and a primary regulator of erythropoiesis that is used for the treatment of chronic anaemia associated with RA (rheumatoid arthritis). Erythropoietin also appears to modulate a broad array of cellular processes, including progenitor stem-cell development, cellular integrity, angiogenesis and oxidative damage. These divers...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید